Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hutchmed (China) Seeks to Raise More Than US$600 Million in Hong Kong IPO

06/17/2021 | 08:32pm EDT

By P.R. Venkat

Hutchmed (China) Ltd. is planning to raise more than US$600 million through a listing in Hong Kong, becoming the latest U.S.-listed Chinese company seeking to tap the Asian financial center's equity market.

Hutchmed (China), which is majority-owned by conglomerate CK Hutchison Holdings Ltd. and specializes in treatments for cancer and immunological diseases, is planning to sell 104 million shares to raise up to 4.68 billion Hong Kong dollars (US$602.8 million), it said Friday.

The Nasdaq-listed company has set a maximum offer price of HK$45 a share.

The planned IPO is the latest in a string of multi-billion-dollar deals happening in Hong Kong, many of which involve Chinese technology startups or other companies catering to China's increasingly affluent consumers.

Earlier this year Tencent Holdings Ltd.-backed Kuaishou Technology, which competes with ByteDance Ltd., raised US$5.4 billion in an IPO. Other companies such as Baidu Inc., which is listed on the Nasdaq, raised nearly US$3.1 billion in its Hong Kong offering.

Hutchmed said Friday that five cornerstone investors, including the Carlyle Group Inc., Canada Pension Plan Investment Board and General Atlantic, had agreed to subscribe to nearly HK$2.54 billion worth of shares ahead of the offering.

The company intends to use the IPO proceeds to fund its business expansion and potential M&A.

Hutchmed expects to finalize the IPO price on June 23 and shares are likely to start trading on the Hong Kong Exchange from June 30.

Morgan Stanley, Jefferies and Credit Suisse are among the banks advising Hutchmed on the offering.

Write to P.R. Venkat at venkat.pr@wsj.com

(END) Dow Jones Newswires

06-17-21 2031ET

Stocks mentioned in the article
ChangeLast1st jan.
CK HUTCHISON HOLDINGS LIMITED 0.70% 57.2 End-of-day quote.5.73%
HUTCHMED (CHINA) LIMITED -0.41% 605.5 Delayed Quote.32.17%
All news about HUTCHMED (CHINA) LIMITED
07/28HUTCHMED CHINA : H1 Net Loss Widens Even as Revenue Jumps
MT
07/28HUTCHMED CHINA : Swings to Wider 1H Loss, Revenue Rises; Reaffirms 2021 Targets
MT
07/28HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates (For..
PU
07/28HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates
PU
07/28HUTCHMED CHINA : Reports 2021 Interim Results and Provides BusinessáUpdates
AQ
07/28Hutchmed China Limited Reports Earnings Results for the Half Year Ended June ..
CI
07/28HUTCHMED Limited Provides Revenue Guidance for the Year 2021
CI
07/28HUTCHMED CHINA : — Follows multiple Phase II studies of ORPATHYS« in Asia ..
PU
07/28HUTCHMED CHINA : AstraZeneca Begin Mid-Stage Trial For Gastric Cancer Drug
MT
07/27HUTCHMED CHINA : and AstraZeneca Initiate Phase II Trial of ORPATHYS« in Patient..
AQ
More news
Financials (USD)
Sales 2021 346 M - -
Net income 2021 -261 M - -
Net cash 2021 822 M - -
P/E ratio 2021 -22,5x
Yield 2021 -
Capitalization 7 229 M 7 234 M -
EV / Sales 2021 18,5x
EV / Sales 2022 15,7x
Nbr of Employees 1 280
Free-Float 51,3%
Chart HUTCHMED (CHINA) LIMITED
Duration : Period :
HUTCHMED (China) Limited Technical Analysis Chart | HCM | KYG4672N1198 | MarketScreener
Technical analysis trends HUTCHMED (CHINA) LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 8,45 $
Average target price 9,59 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Christian Hogg Chief Executive Officer & Executive Director
Chig Fung Cheng Chief Financial Officer & Executive Director
Chi Keung To Executive Chairman
Wei Guo Su Executive Director & Chief Scientific Officer
Marek Kania Chief Medical Officer & Managing Director
Sector and Competitors
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED32.17%7 234
JOHNSON & JOHNSON9.46%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.19.42%246 075
NOVARTIS AG0.14%225 528
ELI LILLY AND COMPANY46.06%224 166